RESEARCH DOSSIER
Neurocognitive Disorders and Acquired Cognitive Impairment
Abstract. Neurocognitive disorders comprise clinically consequential changes in acquired cognitive functioning attributable to heterogeneous neurological, vascular, systemic, neurodegenerative, and sometimes reversible processes. This critical narrative monograph examines how acquired decline is defined, distinguished from normal cognitive variation and acute disturbance, measured across domains, assigned etiological hypotheses, and interpreted in relation to everyday independence. Historical formulations, contemporary syndromal and biomarker-based models, longitudinal epidemiology, clinical neuropsychology, neuropathology, therapeutic trials, rehabilitation research, and international care guidance are integrated. The synthesis emphasizes the non-equivalence of a cognitive phenotype, a biological disease, and an individual's functional trajectory. Evidence supports multidimensional assessment, careful characterization of coexisting causes, selected preventive strategies and person-centered interventions, while exposing unresolved problems of prediction, representativeness, measurement equity, biomarker interpretation, and treatment access. The work is a critically structured narrative synthesis of identifiable literature, not a preregistered systematic review or original experiment.
Keywords: neurocognitive disorders; acquired cognitive impairment; dementia; mild cognitive impairment; Alzheimer disease; vascular cognitive impairment; cognitive reserve; neuropsychological assessment; delirium; biomarkers; rehabilitation; cognitive stimulation; care systems; neuropathology
Introduction: The Scientific Problem of Acquired Decline
Human cognition is a coordinated set of capacities for learning, remembering, language, attentional selection, spatial representation, interpretation, and action. Acquired cognitive impairment is a change in the effectiveness or organization of those capacities after an earlier developmental level of functioning has been established. A clinical analysis therefore asks what changed, compared with which baseline, during what period, in which contexts, and with what consequences for meaningful activity. These questions provide more discriminating information than a solitary numerical test result.
The category neurocognitive disorder connects the psychological study of performance to neurological disease, medical evaluation, everyday function, and temporal course. The causal field includes neurodegeneration, cerebrovascular lesions, traumatic injury, infection, inflammatory conditions, systemic metabolic disease, substance and medication effects, and interacting pathologies. The same outward difficulty can arise from different mechanisms: forgetting a scheduled appointment may reflect a failure to encode new information, impaired retrieval, a breakdown of planning, reduced attention, a language problem, or competing demands. This many-to-one mapping makes assessment fundamentally inferential.
This dossier investigates the common scientific problem across etiologies: identifying and explaining acquired change in cognitive organization. It includes the diagnostic literature of major and mild neurocognitive disorders, the syndrome conventionally called dementia, mild cognitive impairment (MCI), and overlapping acquired cognitive deficits. Specialized traumatic brain injury psychosocial rehabilitation remains the subject of a neighboring research dossier; its general cognitive mechanisms enter here as part of the differential framework. The broader The Psyche scientific architecture concerns mental organization in general, whereas this investigation focuses specifically on acquired human cognitive change.
The methodological basis is critical narrative synthesis. Original trials establish what was observed under defined interventions and populations; observational cohorts describe trajectories and associations; neuropathological studies clarify substrates; guidelines provide assessed recommendations within their scope; and reviews assemble evidence while inheriting the biases of constituent studies. Each source class is interpreted for what it can demonstrate. This review does not provide individualized diagnosis or clinical prescriptions.
Definitions, Thresholds, and Clinical Levels
Acquired cognitive decline requires evidence of deterioration from a previous level. Normal aging may alter processing speed, divided attention, or retrieval efficiency, while maintaining independence and much of accumulated knowledge. A diagnosis of neurocognitive disorder additionally relies on meaningful acquired change, corroboration from history and assessment, exclusion or recognition of acute confounding conditions, and classification by functional impact. The threshold is multidimensional: a sharp deviation from an individual's earlier occupational ability may matter even when a population-standardized score falls near the statistical mean.
The commonly used distinction between mild and major neurocognitive disorder centers on functional consequences. In mild impairment, the person generally remains independent in everyday activities, although tasks may require additional effort, compensatory methods, or more time. In major impairment, cognitive deficits interfere substantially with independence. The term dementia usually describes an acquired syndrome of cognitive decline with meaningful daily-life consequences and has historically emphasized multiple affected domains; contemporary definitions and disease models accommodate varied presentations. The older label senility has no useful explanatory standing as a diagnostic cause.
MCI is a clinical construct rather than a single disease. In the landmark cohort description, Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. (1999) analyzed a state between expected aging and dementia, particularly in memory. Later research broadened phenotypes to include amnestic and nonamnestic, single-domain and multidomain impairment. These distinctions describe cognitive expression and may help generate etiological hypotheses, yet diagnostic thresholds, referral settings, education, and population composition materially influence which people enter an MCI group.
A biological disease, a clinical syndrome, and a severity stage constitute related but separately measured levels. Biomarker evidence of Alzheimer pathophysiology can appear without present cognitive impairment; conversely, clear cognitive decline can have a cause other than Alzheimer disease. The Jack, C. R., Jr., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B. (2018) formalized a biological research definition, and the Jack, C. R., Jr., Andrews, J. S., Beach, T. G., Buracchio, T., Dunn, B., (2024) expanded the biomarker and staging concepts. Both require careful attention to the populations, tests, and clinical decisions for which the classification is intended.
Historical Development of the Research Field
Clinical descriptions of acquired failures of memory and reasoning predate modern neurology. The development of pathological anatomy, experimental psychology, standardized mental examinations, and longitudinal population studies progressively converted descriptive syndromes into testable questions about brain systems and disease mechanisms. Twentieth-century debates concerned whether aging, discrete neurological lesions, and degenerative illness should be organized by symptom, presumed cause, or functional disability. These debates remain alive in contemporary disagreements about the appropriate unit of diagnosis.
The clinician-oriented Mini-Mental State Examination of Folstein, Folstein, and McHugh (1975)90026-6) helped standardize brief bedside descriptions of mental status. It provided a common language for grading observed difficulties while also revealing the limits of compressed cognitive measurement. A screening score sums heterogeneous tasks; it cannot by itself determine the molecular cause of impairment or reconstruct an individual's prior functioning.
Petersen and colleagues' Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. (1999) crystallized MCI as a research and clinical construct. The later Nasreddine, Z. S., Phillips, N. A., Bédirian, V., Charbonneau, S., White (2005) addressed detection of relatively subtle cognitive deficits, including executive and visuospatial abilities. Screening improved the efficiency of identifying people who warrant more detailed evaluation, while psychometric questions concerning language, education, repeated testing, and thresholds became increasingly prominent.
The field subsequently moved toward etiologically specific consensus criteria. The Gorno-Tempini, M. L., Hillis, A. E., Weintraub, S., Kertesz, A., Mendez, (2011), the Gorelick, P. B., Scuteri, A., Black, S. E., DeCarli, C., Greenberg, S. M (2011), and the McKeith, I. G., Boeve, B. F., Dickson, D. W., Halliday, G., Taylor, J.-P (2017) illustrate a broader shift from undifferentiated dementia labels to syndrome-specific probability models. Biological biomarkers subsequently made it possible to ask whether clinical phenotype and underlying pathology were aligned. As modern neuropathology shows, their correspondence is important yet incomplete.
Cognitive Domains and Functional Organization
Learning and memory involve encoding, consolidation, storage, retrieval, and strategic monitoring. The profile of a memory complaint therefore matters. Rapid forgetting despite retrieval assistance raises different hypotheses from inconsistent recall that improves with cues. Episodic memory testing may explore immediate versus delayed recall, recognition, intrusion errors, and the effects of structure or interference. Subjective reports add indispensable ecological context but also reflect mood, expectations, sensory functioning, and insight.
Attention comprises sustained vigilance, selective focus, divided allocation, and control over interference. Executive functions include goal maintenance, working memory manipulation, inhibition, planning, flexible switching, and error monitoring. Difficulties in these domains can degrade performance on otherwise intact language or memory tasks. A person who forgets a recipe step because attention repeatedly shifts has a different functional problem from someone who cannot encode the procedure. Attention and executive findings are especially relevant in vascular, parkinsonian, toxic-metabolic, and multifactorial conditions.
Language can be disrupted at the levels of naming, word meaning, grammar, speech production, repetition, reading, or comprehension. Perceptual and spatial changes may compromise object recognition, visual construction, navigation, or interpretation of complex scenes. Social cognition includes recognizing affective cues, inferring intentions, maintaining conversational reciprocity, and adapting behavior to norms. The Gorno-Tempini, M. L., Hillis, A. E., Weintraub, S., Kertesz, A., Mendez, (2011) and Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., (2011) establish the clinical relevance of such nonamnestic phenotypes.
Cognitive capacity is expressed through the interaction of brain systems, tools, routines, social coordination, and environmental demand. Functional independence can be preserved by familiar environments, external memory aids, division of tasks, or support from others. A clinical score and a real-world task therefore capture different but complementary constructs. Assessment must specify the circumstances under which a capacity becomes visible or impaired.
Time, Trajectory, and Heterogeneity
Temporal course is one of the strongest orienting features in acquired impairment. Sudden onset can suggest stroke or another acute event; stepwise change may reflect recurrent vascular insults; insidious progressive decline is common in neurodegeneration; fluctuations call for examination of sleep, delirium, medication exposure, and Lewy body syndromes. These patterns are probabilistic and may overlap, particularly in older adults with several active processes.
Trajectories cannot be reduced to a universal one-way ladder. Some people classified with MCI later meet criteria for dementia; others remain relatively stable or return above a diagnostic threshold, sometimes because a reversible contributor improved and sometimes because the original categorization reflected measurement noise. Follow-up must distinguish real recovery from practice effects, regression to the mean, shifting reference norms, attrition, and changing informant perspectives. The Petersen, R. C., Lopez, O., Armstrong, M. J., Getchius, T. S. D., Gangul (2018) is now marked retired by PubMed and is used here for historical evidence rather than as current clinical authority.
The pace of decline also depends on the outcome selected. An episodic-memory scale, occupational productivity, caregiver-rated behavior, and basic daily activity may change at different times. For a disease-centered study, the endpoint may be biomarker progression; for a person-centered rehabilitation study, the endpoint may be independence in a chosen task. A valid longitudinal model should articulate which kind of change it predicts and when it expects that change to occur.
Epidemiology and the Population Burden
The World Health Organization. (2026) reports that approximately 57 million people lived with dementia worldwide in 2021 and that nearly 10 million new cases arise annually. These figures describe dementia under particular global estimation methods, not the prevalence of every form of acquired cognitive impairment. WHO also reports that a majority of affected people live in low- and middle-income countries and that family and informal care represent a substantial component of the social and economic burden.
Numerators and denominators require discipline. Clinic-based MCI frequencies cannot be read as community prevalence; estimates of poststroke cognitive impairment vary by follow-up interval, stroke severity, diagnostic instruments, and participation. A Zhang, X., Li, H., Li, Y., Hao, X., Yasen, A., Zheng, X., et al. (2026) reported substantial impairment but also extremely high between-study heterogeneity, making a single pooled percentage a poor substitute for context-specific estimates. Likewise, different diagnostic criteria and population age structures alter dementia prevalence comparisons across time and countries.
Risk and clinical impact are not distributed uniformly. Educational opportunity, cardiovascular exposures, traumatic injury, hearing and vision care, socioeconomic inequality, access to timely assessment, gendered care burdens, and survival with chronic illness shape the population picture. Epidemiology must therefore examine conditions producing vulnerability and detection alongside biological disease. The scientific aim is to explain observed variation through appropriate study design rather than interpret every group difference as an inherent biological property.
Explanatory Frameworks and Cognitive Reserve
Three explanatory levels are indispensable. The first is pathophysiology: protein aggregation, cerebrovascular injury, synaptic loss, inflammation, network disruption, or other disease mechanisms. The second is cognitive systems: how lesions and physiological alterations affect distributed processes of memory, attention, language, and control. The third is adaptive function: how persons accomplish goals in environments containing supports, barriers, habits, and relationships. A causal interpretation becomes stronger when observations across these levels converge.
The concept of cognitive reserve addresses variable clinical expression in the presence of comparable brain changes. Stern (2012)70191-6) discussed reserve as individual variation in the capacity to use cognitive processing and neural resources in ways that sustain function despite pathology. Educational attainment, occupational complexity, and intellectually engaging activity have been studied as correlates and potential contributors. They are imperfect proxies influenced by childhood conditions, opportunity, socioeconomic status, and selection effects. Reserve is an explanatory research construct, not a guaranteed personal protective asset.
Multicausal models also explain why different people with similar pathology experience different impairment. Vascular disease can add to neurodegenerative change; sleep disorders can intensify attentional problems; sensory limitations can distort test performance; depression can alter motivation and concentration; and caregiving environments can modify daily-life demands. The Arvanitakis, Z., Shah, R. C., & Bennett, D. A. (2019) situates diagnostic and management questions within such multifactorial clinical reality. A satisfactory theory must accommodate biological multiplicity, cognitive specificity, and environmental context without assuming that one level subsumes the others.
Alzheimer Disease: Clinical Phenotypes and Biology
Alzheimer disease (AD) has been approached historically through a clinical-pathological association between progressive cognitive decline and characteristic amyloid and tau changes. The field has moved from probabilistic bedside syndromes toward in vivo biological descriptions, while retaining the practical necessity of interpreting the person’s symptoms, function, and competing diagnoses. The Jack, C. R., Jr., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B. (2018) emphasized amyloid, pathologic tau, and markers of neurodegeneration as research constructs. The Jack, C. R., Jr., Andrews, J. S., Beach, T. G., Buracchio, T., Dunn, B., (2024) revised the biomarker system to reflect technological changes, including certain blood assays, and developed a continuum of biological and clinical stages.
These frameworks have important conceptual consequences. An asymptomatic person may show convincing biomarkers of pathology, whereas another may experience substantial memory impairment for reasons unrelated to AD. A positive biological test answers a particular question about pathophysiology; it does not automatically forecast an individual’s rate of decline, identify the total causes of a disability, or establish the value of a proposed treatment. Test specificity for a biomarker reference standard also differs from specificity for a future clinical outcome. The distinction is central to counseling and research consent.
Typical amnestic presentations feature inefficient formation or retention of new episodic memories, but AD can also present with progressive language, visuospatial, behavioral, or executive difficulties. The Jack, C. R., Jr., Andrews, J. S., Beach, T. G., Buracchio, T., Dunn, B., (2024) explicitly describe multiple phenotypes. This variability arises from differences in anatomical involvement, disease stage, reserve, and coexisting pathology. Investigators must specify whether a sample was selected by clinical phenotype, pathological findings, biomarker thresholds, or a combination; otherwise, studies may appear to disagree because they enrolled fundamentally different populations.
At the molecular level, amyloid-beta accumulation and abnormal tau processes are central to the prevailing biological account. Their timing, localization, and relationships with synaptic dysfunction, glial response, vascular integrity, and neuronal loss remain active research questions. The existence of target-engaging treatment trials strengthens specific mechanistic arguments while leaving many questions about downstream pathways and individualized benefit unsettled. A mechanistic model must be assessed against converging longitudinal, experimental, imaging, and pathological evidence.
Vascular and Poststroke Cognitive Impairment
Vascular cognitive impairment (VCI) refers to cognitive disturbance associated with cerebrovascular disease, ranging from measurable deficits with preserved independence to major functional impairment. Mechanisms include strategic infarcts, multiple cortical or subcortical lesions, small-vessel disease, white matter injury, hemorrhage, hypoperfusion, and secondary network disconnection. Distinct vascular mechanisms may yield overlapping clinical profiles, and their location can matter as much as the volume of injury.
The Gorelick, P. B., Scuteri, A., Black, S. E., DeCarli, C., Greenberg, S. M (2011) helped establish a framework that connects vascular risk, imaging evidence, cognition, and dementia. Executive dysfunction, slowed processing, attention deficits, and complex-task inefficiency frequently attract attention, although memory problems may also be prominent. Stroke-related deficits are shaped by premorbid function, lesion location, additional disease, mood, rehabilitation opportunities, and the conditions of measurement.
Research after stroke also highlights the limits of aggregate prevalence. A Zhang, X., Li, H., Li, Y., Hao, X., Yasen, A., Zheng, X., et al. (2026) on first-stroke patients synthesized 11 publications and 7,048 participants, reporting a pooled estimate of 46% with a 95% confidence interval of 36%–57% and I-squared approximately 98.6%. These values describe the sampled evidence and its marked inconsistency; they should not be transferred directly to all stroke survivors, healthcare systems, or follow-up intervals. Study differences in ascertainment, case mix, and instruments require explanation.
Vascular impairment is also a model case for causal complexity. Hypertension, diabetes, smoking, lipid disorders, and other exposures may affect vascular injury and coexist with neurodegeneration. Observational associations generate questions about prevention; randomized interventions offer stronger evidence of causal effects on specified cognitive endpoints. The contribution of lesion burden, inflammation, network effects, and reserve should be evaluated jointly rather than forcing mutually exclusive etiological classifications.
Lewy Body and Parkinsonian Cognitive Syndromes
Dementia with Lewy bodies (DLB) is recognized through a distinctive combination of cognitive, perceptual, behavioral, sleep-related, and motor phenomena, with substantial interindividual variation. Fluctuating cognition, recurrent well-formed visual hallucinations, spontaneous parkinsonism, and REM sleep behavior disorder are central clinical features, while biomarkers provide additional diagnostic support. The McKeith, I. G., Boeve, B. F., Dickson, D. W., Halliday, G., Taylor, J.-P (2017) refined the weighting of signs and indicators and underscored the need to integrate clinical manifestations with diagnostic tests.
Cognitive expression often involves attention, executive processing, and visuospatial abilities. Fluctuation is particularly challenging for one-time evaluation: performance may differ by time of day, fatigue, sleep disruption, medications, or the presence of superimposed illness. Measurement should seek repeated observations and history from people who know the individual’s ordinary patterns, while remaining attentive to the patient’s own account.
Parkinsonian cognitive syndromes encompass impairment occurring in the context of Parkinson disease and associated conditions. Diagnostic timing and the sequence of motor and cognitive symptoms have traditionally been used to differentiate certain syndromal classifications, but biological processes and mixed pathologies often cross those clinical boundaries. Studies should declare the operational rule used for classification and avoid reading the rule as an exhaustive statement about underlying biology.
Treatment and care studies must evaluate neuropsychiatric symptoms, falls, sleep, autonomic dysfunction, and drug sensitivity along with cognition. The clinical relevance of particular interventions depends on this wider symptom configuration. Any claims about medication-specific benefits and harms require confirmation against current regulatory labels and population-specific evidence rather than extrapolation from studies of Alzheimer disease alone.
Frontotemporal Syndromes and Progressive Aphasia
Frontotemporal degeneration provides a clear counterexample to the idea that major acquired cognitive impairment begins with forgetting. In behavioral-variant frontotemporal dementia, early manifestations may concern disinhibition, reduced empathy, perseveration, altered eating behavior, impaired social judgment, or apathy. The Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., (2011) distinguished levels of clinical diagnostic certainty and examined the sensitivity of revised criteria in a pathologically confirmed cohort.
Primary progressive aphasia (PPA) describes a language-led pattern of progressive cognitive dysfunction. The Gorno-Tempini, M. L., Hillis, A. E., Weintraub, S., Kertesz, A., Mendez, (2011) organized three principal variants—nonfluent/agrammatic, semantic, and logopenic—using language profiles and supporting imaging or pathology. The classification expresses probabilistic relationships: different proteinopathies can underlie related syndromes, and a phenotype is not equivalent to a definitive molecular diagnosis.
Assessment must characterize language with sufficient granularity. Naming, semantics, grammatical processing, repetition, spontaneous speech, phonological working memory, and reading may dissociate. Severe language impairment can also invalidate cognitive screening scores that depend on verbal instructions or output. Apparent global impairment may partly reflect a poorly matched measurement instrument.
Social and family consequences are often substantial when communication or judgment changes precede widely recognized memory difficulties. Caregiver narratives can reveal altered interpersonal behavior and loss of accustomed reciprocity, while patient self-report may remain crucial even if insight varies. Research should include adaptive communication, caregiver strain, ethical decision-making, and community participation rather than treating the syndrome only as a localization exercise.
Mixed Pathologies, LATE, and Diagnostic Complexity
Multiple pathological processes commonly coexist in aging brains, creating the possibility that a person’s symptoms reflect several interacting disease mechanisms. Amyloid and tau changes, vascular lesions, Lewy pathology, hippocampal injury, and other proteinopathies may jointly shape clinical outcomes. The same clinical category may therefore contain individuals with different mixtures of pathology, while distinct clinical labels may share biological contributors.
The Nelson, P. T., Dickson, D. W., Trojanowski, J. Q., Jack, C. R., Boyle, P (2019) described a TDP-43-related pathological process associated with an amnestic clinical picture that can resemble Alzheimer-type dementia in older people. Its importance lies partly in demonstrating why memory-predominant symptoms cannot identify one proteinopathy with certainty. Clinicopathological observations motivate research into in vivo biomarkers and more discriminating combinations of tests.
Diagnostic uncertainty is therefore an empirical property of the object, not merely a temporary failure of the assessor. A useful report can state which syndrome is observed, what causal findings support particular mechanisms, which alternative processes remain plausible, and what confidence is justified. This layered reasoning is especially important when disease-modifying medications are restricted to biomarker-confirmed populations and carry serious risks.
Mixed-pathology research also changes the interpretation of negative tests. Absence of evidence for one target mechanism does not eliminate the patient’s observed cognitive impairment or identify its cause. Equally, positive evidence for one process may leave open the contribution of another. Bayesian clinical reasoning and longitudinal reassessment offer a more accurate framework than simple one-test classification.
Other Acquired Causes and Potential Reversibility
Acquired cognitive impairment may follow traumatic brain injury, central nervous system infection, inflammatory or autoimmune disease, seizures, toxic exposure, substance use, medication adverse effects, nutritional deficiency, thyroid disturbance, sleep-disordered breathing, and systemic organ dysfunction. Some contributors are directly treatable; others create persistent deficits even after the precipitating event has resolved. The clinical investigation therefore requires chronology, physical and neurological examination, medication reconciliation, and targeted testing rather than reflexive attribution to age or a common neurodegenerative condition.
The adjective reversible requires precision. Correcting a contributing factor may improve attention or memory without restoring earlier functioning entirely, and a reversible process can coexist with an irreversible one. Similarly, improvement after treatment does not always prove that the treated factor caused the full syndrome, because practice effects, spontaneous recovery, and changes in sleep, mood, or support may also contribute.
Acquired brain injury research introduces an important rehabilitation perspective: cognitive outcomes are mediated by lesion characteristics, compensatory learning, adaptation, family support, and social opportunity. A dedicated study of traumatic and other acquired brain injury psychosocial rehabilitation addresses these pathways in depth. Within this dossier, brain injury is examined as an acquired causal category and a source of general insight into functional reconstruction.
Urgent acute or rapidly progressive changes warrant a different clinical response from slowly emerging symptoms, since delirium, stroke, infection, and other potentially serious causes may be involved. This statement establishes a diagnostic principle, not a personalized triage algorithm or a recommendation about a particular patient's treatment.
Delirium, Depression, and Differential Diagnosis
Delirium is an acute, often fluctuating disturbance in attention and awareness accompanied by additional cognitive changes, generally linked to an underlying medical or physiological insult. Its temporal pattern and attentional abnormalities are critical. Inouye, Westendorp, and Saczynski (2014)60688-1) synthesized the clinical and mechanistic literature and emphasized the value of multifactorial approaches to prevention. Delirium can coexist with dementia; identifying one does not exclude the other.
Depression can impair concentration, processing efficiency, motivation, and memory performance, and may also precede or accompany neurodegenerative illness. A report of forgetfulness in a person experiencing low mood therefore calls for joint assessment of affective symptoms and cognition. Neuropsychological patterns may offer clues but do not replace longitudinal history, clinical evaluation, and attention to co-occurring conditions. Simple binary accounts of depressive versus organic cognitive impairment obscure their interaction.
Sleep loss, anxiety, pain, sensory impairment, medication effects, and fatigue can produce additional confounding. A low score under these conditions may register genuine functional difficulty while providing limited evidence of progressive neurodegeneration. Conversely, an apparently reassuring result on a brief test does not resolve a well-corroborated history of decline in complex real-world tasks.
The differential process is strongest when evidence is triangulated: onset and course, informant observation, domain-specific examination, functional history, neurological signs, laboratory and imaging findings when indicated, and repeat assessment. Arvanitakis, Z., Shah, R. C., & Bennett, D. A. (2019) present this broad clinical logic in their review of dementia diagnosis and management. The central goal is an explanatory profile grounded in multiple observations rather than premature certainty from one instrument.
Clinical History and Multisource Assessment
Evaluation begins by reconstructing baseline and change. The assessor asks when difficulties first appeared, which activities were affected, how symptoms evolved, what neurological and medical events occurred, and which changes have been independently noticed. The history must distinguish lifelong learning patterns, developmental disability, educational exclusion, and language differences from acquired decline. In some cases a former occupational activity provides a more revealing comparator than broad age norms; in others, household routines and social participation reveal impairment missed by formal testing.
Information from the person under evaluation is essential. Family members, care partners, coworkers, and other informants may offer complementary observations, particularly regarding fluctuations, safety incidents, financial tasks, or behavioral change. Informant accounts also have biases: distress, limited contact, expectations about aging, and cultural beliefs can influence estimates of ability. The aim is to identify agreement, disagreement, and the circumstances behind each report, rather than privileging one perspective automatically.
Clinical assessment includes relevant medical, neurological, psychiatric, sleep, sensory, medication, substance exposure, and functional histories. A physical examination may identify gait abnormalities, parkinsonism, focal findings, or signs of systemic illness. Laboratory investigations and structural neuroimaging are chosen to answer defined differential questions. Comprehensive evaluation is a process of progressively reducing uncertainty; unnecessary testing may generate incidental findings or interpretations detached from clinical context.
The Atri, A., Dickerson, B. C., Clevenger, C., Karlawish, J., Knopman, D., L (2025) organizes the methodological role of cognitive and functional assessment within diagnostic evaluation. Such guidance illustrates how psychometric evidence, clinician judgment, and communication with patients and families should be integrated. The validity of an inference depends on the population, language, task demands, and purpose for which a tool has been evaluated.
Cognitive Screening and Neuropsychological Measurement
Brief screening scales are designed to flag possible impairment under time constraints. The Mini-Mental State Examination (Folstein et al., 1975)90026-6) and Nasreddine, Z. S., Phillips, N. A., Bédirian, V., Charbonneau, S., White (2005) are historically important examples. Their total scores summarize performance across selected tasks, with properties influenced by educational attainment, language, sensory and motor requirements, disease stage, and sampling conditions. They are measurements of performance under a particular protocol, not direct observations of pathology.
A full neuropsychological examination seeks a domain profile rather than a single global number. Tests may distinguish learning from delayed retention; verbal from nonverbal memory; semantic from phonological language; processing speed from higher-level executive control; visual construction from perception; and performance-based function from self-reported independence. Convergent indicators strengthen hypotheses, while dissociations can direct attention to particular networks or disease presentations.
Interpretation requires attention to normative reference groups and measurement error. A low standardized score may occur in cognitively healthy people when numerous tests are administered; a normal score may conceal decline in a person whose premorbid performance was substantially higher. Multiple comparisons, base rates of low scores, practice effects, and test–retest reliability all influence clinical conclusions. Whenever possible, the evaluator should report change and its uncertainty rather than turning an arbitrary cutoff into a categorical biological truth.
Sensitivity and specificity vary with thresholds and the population examined. A tool validated in a specialty memory clinic can perform differently in primary care or community screening because the underlying distribution of causes and disease probability differs. Positive and negative predictive values depend on prevalence; comparative accuracy studies should identify their reference standard, sampling frame, verification procedures, and blinding. Diagnostic performance for one classification does not imply equal predictive value for future dementia.
Functional, Behavioral, and Contextual Evaluation
Functional assessment asks how acquired difficulties affect everyday life. Instrumental activities include financial management, medication organization, transportation, technology use, shopping, scheduling, and household administration; basic activities include dressing, feeding, bathing, and other essential self-care. Dependence may arise through combinations of cognitive, physical, sensory, social, and environmental barriers. An estimate of functional impairment should therefore document both the task and the reason it is difficult.
Activities that appear intact in an extensively supported household may conceal a substantial reduction in unassisted capacity. At the same time, successful compensation is a meaningful outcome, not a defect in assessment. A family calendar, simplified medication system, communication board, or trusted collaborator can preserve autonomy. Research benefits from distinguishing intrinsic performance, aided performance, and actual participation under usual conditions.
Behavioral and psychological manifestations can include apathy, agitation, sleep disruption, anxiety, depressed mood, psychosis, disinhibition, and altered social understanding. These phenomena have different etiologies and may be amplified by pain, communication barriers, environmental overload, or unmet needs. A symptom inventory should not replace a causal formulation. It should guide examination of triggers and contexts, document the person's experience, and establish outcomes that matter to both the person and those providing assistance.
Caregiver-based measures create additional interpretation challenges because a burden score combines the care recipient's needs with family resources, employment, health, and social support. A study reporting reduced caregiver burden has not necessarily demonstrated reversal of cognitive decline. Distinguishing endpoints allows clinical and social outcomes to be understood without overclaiming biological change.
Neuroimaging, Fluid Biomarkers, and Diagnostic Inference
Structural imaging can reveal infarcts, hemorrhage, mass lesions, characteristic atrophy, hydrocephalus, and other findings relevant to differential diagnosis. MRI also supports description of white matter changes and strategic lesions. Patterns may strengthen hypotheses, but many findings lack disease-specificity in isolation. Imaging evidence is interpreted alongside age, medical history, examination, and cognitive phenotype; incidental abnormalities can complicate causal attribution.
Molecular imaging and fluid biomarkers address more specific pathophysiological questions. Amyloid PET, selected cerebrospinal fluid tests, tau-oriented measures, and certain plasma biomarkers have been incorporated into contemporary Alzheimer disease frameworks. The Jack, C. R., Jr., Andrews, J. S., Beach, T. G., Buracchio, T., Dunn, B., (2024) expanded the role of early-changing disease markers while noting the limits of interchangeability between assays and their intended uses.
A Palmqvist, S., Whitson, H. E., Allen, L. A., Suárez-Calvet, M., Galasko, (2025) evaluated blood-based biomarkers specifically in specialized care of patients with objective cognitive impairment and suspected Alzheimer pathology. It proposed performance requirements for use as triage tests and for substitution of established amyloid PET or cerebrospinal fluid reference methods. The guideline warns that many commercial assays differ materially in accuracy and that testing complements comprehensive clinical evaluation. Its recommendations should not be automatically transferred to asymptomatic screening, untrained settings, or other neurodegenerative diseases.
Biomarker research faces a series of linked inferential problems. An assay may accurately detect a biological state yet be less informative about the timing or form of future symptoms. Predictive value is affected by pretest probability, age, coexisting disease, assay calibration, and cutoffs. When a reference standard is itself imperfect, estimated accuracy can misrepresent clinical utility. Longitudinal studies must test incremental prediction beyond available clinical information, as well as downstream effects of testing on patient decisions, health outcomes, cost, and equity.
Longitudinal Research and Evidence Quality
The key designs in this field answer different questions. Cross-sectional studies describe associations and case-control contrasts; prospective cohorts establish temporal sequences and estimate transitions; pathology-linked studies strengthen disease attribution; randomized trials test defined interventions; qualitative work investigates lived experience and the meaning of functional changes. No single design resolves every issue. A convincing evidence synthesis must align the research question with the design capable of answering it.
Longitudinal cognitive datasets are especially vulnerable to selective attrition. Participants with severe impairment, illness, institutionalization, or social disadvantage may be less likely to complete repeated testing. If attrition is related to the outcome, observed average trajectories can appear more favorable than the underlying population course. Death is also a competing event. Missing-data methods, sensitivity analyses, and transparent recruitment and follow-up reporting are necessary for defensible inference.
Misclassification can distort estimates of both prognosis and treatment benefit. A cohort defined by a single low screening score includes measurement variability and diverse causes of poor performance; a specialty sample defined by biomarkers includes a different spectrum. Across studies, apparent disagreement may reflect definitions, follow-up duration, recruitment, availability of imaging or pathology, and differences in functional thresholds. Pre-registered outcomes and replication across settings help establish which findings generalize.
Publication bias and selective analysis remain relevant even when studies use sophisticated assays. Small biomarker discovery studies can exaggerate diagnostic accuracy; flexible cutoffs can optimize performance retrospectively; unblinded assessments can amplify expectancy effects; and surrogate changes may receive more attention than actual function. Evidence assessment should inspect protocols, exclusions, comparators, prespecified endpoints, harms, conflicts of interest, and external validation.
Culture, Language, Disability, and Assessment Equity
Cognitive tests are cultural and linguistic instruments as well as neurological probes. Vocabulary, formal education, familiarity with timed testing, literacy, migration history, sign language, bilingual language allocation, and access to schooling all affect test behavior. Translating words does not necessarily preserve difficulty or construct equivalence. Validation requires representative sampling, culturally appropriate norms, and examination of differential item functioning.
Sensory and motor limitations can produce apparent cognitive failure in visually, auditorily, or manually demanding tasks. People with hearing loss may miss instructions; visually impaired participants may be unable to complete construction tasks; aphasia may prevent verbal reporting despite preserved nonverbal abilities. Accessible adaptation should maintain a clear record of what task changes imply for score comparability. Where standardized inference is weakened, multiple qualitative and functional observations become more important.
Diagnostic inequality emerges when access to specialist assessment, advanced imaging, and biomarker assays is distributed unevenly. Populations underrepresented in assay validation may be exposed to uncertain thresholds or delayed diagnosis. A scientific claim of universality demands evidence that measurement performs sufficiently well across settings, rather than the assumption that an instrument validated in a wealthy academic clinic transfers unchanged.
Equity also concerns the consequences of labeling. Diagnosis can unlock support and planning, but can also alter employment, insurance, legal treatment, family expectations, and personal identity. Research ethics should treat autonomy, informed consent, language access, and supported decision-making as substantive aspects of care. Careful clinical communication explains what is known, which possibilities remain open, and what a test actually measures.
Prevention and Modification of Population Risk
Prevention research asks whether altering exposures changes the incidence, onset, or clinical expression of acquired cognitive impairment. Observational associations help identify candidate targets, but their causal interpretation is limited by confounding, reverse causation, measurement error, and changes in health behavior during the preclinical course of disease. A strong intervention design must specify the population's baseline risk, the exposure modified, a realistic follow-up period, and endpoints that capture cognitive or clinical change rather than exposure change alone.
The 2024 Lancet standing Commission report by Livingston and colleagues01296-0) assembled evidence for potentially modifiable dementia risk factors across the life course and emphasized prevention, intervention, and care as interconnected priorities. Its estimates of potentially preventable population burden are model-dependent counterfactual scenarios, not promises that any individual's dementia can be prevented. Such estimates incorporate assumptions about causal relationships, factor prevalence, and overlap among risks. They are especially valuable for framing public-health decisions when interpreted alongside uncertainty and distributional effects.
Randomized evidence adds necessary specificity. The FINGER trial (Ngandu et al., 2015)60461-5) evaluated a multidomain intervention involving dietary guidance, exercise, cognitive training, and vascular risk monitoring in at-risk older adults. The study contributed evidence that a coordinated approach can improve specified cognitive outcomes under trial conditions. Its population selection, intervention intensity, outcome battery, and length of follow-up matter when assessing generalization to other ages, social settings, or clinical disease stages.
The SPRINT MIND Investigators for the SPRINT Research Group. (2019) examined intensive versus standard blood-pressure control in adults with hypertension. It reported a statistically significant reduction in adjudicated MCI, whereas the reduction in the prespecified probable dementia outcome did not reach conventional statistical significance. The study's early intervention termination and lower-than-expected dementia-event count limit interpretation. Its results show why a beneficial secondary cognitive outcome cannot be reported as proof of an effect on every dementia endpoint.
Population strategies may include attention to cardiovascular health, physical activity, education, sensory care, environmental exposures, and social conditions, with the evidence differing by intervention and endpoint. The World Health Organization. (2026) updates the 2019 framework, addressing environmental exposures, tailored multidomain approaches, cardiovascular risk management, and cognitive and social interventions. Its population-health recommendations require interpretation in light of differing intervention certainty, local resources, and patient circumstances. The companion World Health Organization. (2026) cautions against routine vitamin E/B or omega-3 supplements as dementia-prevention strategies in the absence of deficiency; scientific writing should distinguish these population-level recommendations from an individual's treatment decisions.
Psychosocial and Cognitive Interventions
Psychosocial care addresses cognition, participation, mood, communication, identity, activity, and interpersonal support. Its outcomes should be described according to the intervention's actual aim: improvement on a cognitive test, performance of a personally relevant task, reduced distress, greater participation, or altered caregiver experience are distinct achievements. The same intervention can improve one outcome while leaving another unchanged.
Cognitive stimulation therapy offers a historically significant example. In a Spector, A., Thorgrimsen, L., Woods, B., Royan, L., Davies, S., Butterwo (2003) investigated a structured group cognitive stimulation program for people with dementia. The study reported favorable results on certain cognitive and quality-of-life measures relative to control conditions. The effects were measured over a specified trial period; they should not be interpreted as evidence of reversal of neurodegenerative pathology. Subsequent guideline recommendations must be read in relation to disease stage, patient preferences, and local service capacity.
Goal-oriented cognitive rehabilitation pursues everyday functioning through individualized goals, compensatory methods, environmental modification, and supported practice. The Clare, L., Kudlicka, A., Oyebode, J. R., Jones, R. W., Bayer, A., Leroi, (2019) studied individualized cognitive rehabilitation in early-stage dementia. Its design directs attention to functional outcomes selected with participants and care partners, which differ from the endpoints of generalized brain-training products. Success may consist of regaining a routine through strategic support rather than improving every neuropsychological measure.
The NICE dementia guideline NG97, reviewed in October 2025 without a decision to update, includes recommendations on personalized activities, group cognitive stimulation, consideration of reminiscence therapy, and cognitive rehabilitation or occupational therapy. These recommendations have particular populations and evidentiary bases. Other interventions such as unstructured cognitive training, commercially marketed digital exercises, or noninvasive stimulation require separate evaluation rather than receiving credibility through loose association with established rehabilitation approaches.
Psychological interventions for mood and behavioral symptoms also require careful etiological framing. Agitation may be a response to pain, fear, environmental demands, or communication difficulty. Apathy may reflect disease-linked motivational processes rather than an intentional refusal to act. Person-centered behavioral formulation seeks modifiable triggers and meaningful supports while recognizing the limits of any single treatment technique. Studies should report fidelity, adverse effects, access, caregiver time, and durability of benefit.
Medication, Disease Modification, and Safety
Pharmacological approaches to neurocognitive disorders address heterogeneous targets. Symptomatic agents used in selected dementia syndromes seek to modify neurotransmission or associated symptoms, whereas disease-modifying approaches attempt to change underlying pathological pathways. Efficacy must be evaluated with the study population, disease stage, comparator, measured benefit, follow-up duration, and harms specified. Medication choice, eligibility, monitoring, and discontinuation remain clinical matters governed by the applicable evidence, product information, and jurisdiction.
Trials of monoclonal antibodies against amyloid illustrate both a major advance and a methodological challenge. In the van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Ge (2023) evaluated lecanemab in biomarker-confirmed early Alzheimer disease. In the Sims, J. R., Zimmer, J. A., Evans, C. D., Lu, M., Ardayfio, P., Sparks, (2023) evaluated donanemab in early symptomatic disease with selected biomarker characteristics. Both trials studied specified patient populations rather than the full spectrum of dementia or acquired cognitive impairment, and reported differences on composite clinical decline measures over limited follow-up.
Interpretation requires distinguishing slower average decline from restoration of lost function. A between-group difference on a clinical rating scale can indicate meaningful treatment action while still requiring analysis of effect magnitude, scale properties, clinical importance, individual variability, treatment burden, and long-term outcome. The trial populations and exclusion criteria also constrain generalization to people with substantial vascular disease, other cognitive etiologies, or high-risk comorbidities.
Safety is inseparable from the evidence. Amyloid-related imaging abnormalities (ARIA), including edema and hemorrhagic changes, appear in regulatory warnings for anti-amyloid antibodies; severe and potentially fatal events are recognized. Risk varies by genotype, cerebral vascular features, treatment, and other individual factors. The current DailyMed U.S. label for donanemab and European Medicines Agency Kisunla documentation establish that regulatory information is product-, date-, and jurisdiction-specific. This dossier does not extrapolate those approvals to all neurocognitive disorders, nor present dosing or treatment-selection advice.
A research account should also examine who bears monitoring costs and whether infrastructure exists for specialist confirmation, imaging, and follow-up. Therapeutic innovation creates scientific and ethical questions about access and priority setting. Claims of benefit are strongest when they incorporate patient-relevant endpoints, complete harms reporting, and comparative effectiveness in representative clinical populations.
Families, Caregiving, Autonomy, and Participation
Acquired cognitive impairment changes household routines, role allocation, financial decisions, communication, and the relationship between independence and support. A person may maintain decision-making capacity in some domains while needing help in others. Capacity is task-specific and context-sensitive; a diagnostic label alone does not determine competence for every decision. Supported communication and appropriately structured choices may preserve participation that would otherwise be hidden by a hurried or inaccessible interaction.
Caregiving relationships are dynamic. Time demands, emotional burden, work disruption, physical health, and financial strain depend on disease characteristics and on the availability of services. Family assistance can enable meaningful autonomy, yet it may also create stress and unequal responsibilities. The World Health Organization. (2026) documents the substantial international role of informal caregivers and the uneven distribution of care work, supporting analysis beyond a purely individual neurological model.
Psychological adjustment concerns identity, confidence, anticipated stigma, anxiety about future decline, and continuity of personally meaningful goals. Someone whose cognitive abilities change may still communicate preferences, recognize emotional relationships, participate in routines, and contribute to decisions. A comprehensive research strategy asks which forms of agency persist and how environments support them. Functional independence is an important outcome, but participation, dignity, and quality of life cannot be reduced to an independence score.
Service organization affects outcomes through timely assessment, continuity of care, training, respite, accessible transport, community participation, and caregiver support. Evaluations should distinguish improvements generated by effective clinical interventions from those generated by social and environmental redesign. Both can be meaningful without claiming to eliminate the underlying disease.
Research Gaps, Artificial Systems, and Future Methods
The most consequential methodological gap is the prediction of individual trajectories from incomplete and multilevel evidence. Biomarkers may identify pathology, yet the transition to symptoms varies. Neuropsychological tests describe particular abilities in constrained settings, yet everyday functioning depends on habits, environmental tools, care networks, and fluctuating health. Mechanistic modeling must connect molecular processes, network function, task performance, and actual participation without treating correlation as proof of a complete causal chain.
Digital assessment and artificial systems may support repeated, low-burden observation of language, mobility, daily routines, and cognitive performance. Potential benefits include richer longitudinal sampling and measurement outside the specialist clinic. Their limitations include data missingness, changes in device use, algorithmic drift, privacy loss, biased training populations, and the danger of pathologizing cultural or individual variation. Any automated inference of decline needs prospective validation against appropriate outcomes, transparent performance stratification, human interpretability, and consent-sensitive governance.
Within the Artificial Era, cognitive partnership may change how acquired impairment is compensated. External reminders, adaptive interfaces, navigation assistance, and conversational support can redistribute practical cognitive work between a person, digital tools, and other people. The relevant empirical question is whether a configuration improves person-defined function safely and sustainably. This is an investigable hypothesis about human–artificial interaction, distinct from any claim that artificial systems themselves have human neurocognitive disorders.
Future studies should include low-resource settings, multilingual populations, people with sensory or motor limitations, and individuals with mixed pathologies who are frequently excluded from tightly selected trials. Outcomes should cover actual functioning, treatment burden, caregiver consequences, and long-term adverse events, together with conventional cognition and pathology measures. Registered protocols, open analytic specifications, independent validation cohorts, and accessible reporting would make the evidence more cumulative.
Critical Scientific Synthesis
The evidence supports a structured distinction among four questions: whether acquired decline exists; which cognitive systems are affected; which pathophysiological processes plausibly explain the change; and which functional outcomes and supports matter in the person's circumstances. The questions interact but have separate evidentiary requirements. Strong evidence for amyloid pathology, for example, can improve etiological classification while leaving the magnitude of a person's current daily difficulty to be established by additional observation.
The most reliable diagnostic approach is therefore convergent. Historical change and informant reports, profile-sensitive neuropsychological assessment, physical and neurological findings, targeted imaging and laboratory evidence, selected biomarkers, and longitudinal reconsideration jointly constrain interpretation. No single test supplies all those dimensions. High classification accuracy in a narrow reference sample does not ensure equitable, useful prediction in an unselected population.
Intervention evidence likewise needs alignment between mechanism, endpoint, and meaning. Multidomain prevention trials and blood-pressure trials can inform population-level risk modification for specified groups; cognitive rehabilitation can improve a chosen everyday task without reversing neuropathology; disease-modifying antibodies can affect average decline in biomarker-selected early Alzheimer disease while imposing important risks. These results become misleading when merged into a generic assertion that dementia is preventable, cognitive impairment is reversible, or all patients should receive a given intervention.
A cross-cutting problem concerns the difference between measurement and value. Tests measure selected performances, functional scales measure selected dependencies, and biomarkers measure selected biological signals. An individual may prioritize communication, safety, self-determination, mobility, or relationships. Better science will clarify how these measures align, when they diverge, and whose outcomes shape research priorities. It will also develop models of cognition that accommodate disease processes and the adaptive organization of life outside the clinic.
Conclusion
Neurocognitive disorders and acquired cognitive impairment form a scientifically unified field because they concern loss or alteration of previously established cognitive capacities, even though the underlying diseases, trajectories, and opportunities for intervention are heterogeneous. Their study has advanced through neuropsychological measurement, prospective cohorts, clinicopathological observation, biological biomarkers, controlled treatment trials, and increasingly contextual research on everyday function.
The strongest synthesis treats a cognitive syndrome, its etiological substrate, and the person's lived functioning as connected levels of explanation. Detailed assessment and longitudinal interpretation are necessary to move between them. Evidence favors careful attention to modifiable vascular and social risks, targeted psychosocial supports, individualized rehabilitation goals, and rigorously selected medical interventions, while retaining the outcome-specific and population-specific limits of available trials.
The next stage of research is methodological integration: better representative cohorts, more discriminating disease models, transparent evidence assessment, equitable biomarkers, long-term safety follow-up, and evaluations of adaptive environments. Scientific progress will be measured by improved understanding of acquired cognitive change and by more reliable support for the lives and decisions of those who experience it.
References
- Arvanitakis, Z., Shah, R. C., & Bennett, D. A. (2019). Diagnosis and management of dementia: Review. Journal of the American Medical Association, 322(16), 1589–1599. https://doi.org/10.1001/jama.2019.4782
- Atri, A., Dickerson, B. C., Clevenger, C., Karlawish, J., Knopman, D., Lin, P.-J., et al. (2025). The Alzheimer's Association clinical practice guideline for the diagnostic evaluation, testing, counseling, and disclosure of suspected Alzheimer's disease and related disorders (DETeCD-ADRD): Validated clinical assessment instruments. Alzheimer's & Dementia, 21(1), e14335. https://doi.org/10.1002/alz.14335
- Clare, L., Kudlicka, A., Oyebode, J. R., Jones, R. W., Bayer, A., Leroi, I., et al. (2019). Individual goal-oriented cognitive rehabilitation to improve everyday functioning for people with early-stage dementia: A multicentre randomised controlled trial (the GREAT trial). International Journal of Geriatric Psychiatry, 34(5), 709–721. https://doi.org/10.1002/gps.5076
- Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975). Mini-mental state: A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12(3), 189–198. https://doi.org/10.1016/0022-3956(75)90026-6
- Gorelick, P. B., Scuteri, A., Black, S. E., DeCarli, C., Greenberg, S. M., Iadecola, C., et al. (2011). Vascular contributions to cognitive impairment and dementia: A statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke, 42(9), 2672–2713. https://doi.org/10.1161/STR.0b013e3182299496
- Gorno-Tempini, M. L., Hillis, A. E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S. F., et al. (2011). Classification of primary progressive aphasia and its variants. Neurology, 76(11), 1006–1014. https://doi.org/10.1212/WNL.0b013e31821103e6
- Inouye, S. K., Westendorp, R. G. J., & Saczynski, J. S. (2014). Delirium in elderly people. The Lancet, 383(9920), 911–922. https://doi.org/10.1016/S0140-6736(13)60688-1
- Jack, C. R., Jr., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., et al. (2018). NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimer's & Dementia, 14(4), 535–562. https://doi.org/10.1016/j.jalz.2018.02.018
- Jack, C. R., Jr., Andrews, J. S., Beach, T. G., Buracchio, T., Dunn, B., Graf, A., et al. (2024). Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheimer's & Dementia, 20(8), 5143–5169. https://doi.org/10.1002/alz.13859
- Livingston, G., Huntley, J., Liu, K. Y., Costafreda, S. G., Selbæk, G., Alladi, S., et al. (2024). Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. The Lancet, 404(10452), 572–628. https://doi.org/10.1016/S0140-6736(24)01296-0
- McKeith, I. G., Boeve, B. F., Dickson, D. W., Halliday, G., Taylor, J.-P., Weintraub, D., et al. (2017). Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology, 89(1), 88–100. https://doi.org/10.1212/WNL.0000000000004058
- Nasreddine, Z. S., Phillips, N. A., Bédirian, V., Charbonneau, S., Whitehead, V., Collin, I., Cummings, J. L., & Chertkow, H. (2005). The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment. Journal of the American Geriatrics Society, 53(4), 695–699. https://doi.org/10.1111/j.1532-5415.2005.53221.x
- National Institute for Health and Care Excellence. (2018; reviewed 2025). Dementia: Assessment, management and support for people living with dementia and their carers (NG97). https://www.nice.org.uk/guidance/ng97
- Nelson, P. T., Dickson, D. W., Trojanowski, J. Q., Jack, C. R., Boyle, P. A., Arfanakis, K., et al. (2019). Limbic-predominant age-related TDP-43 encephalopathy (LATE): Consensus working group report. Brain, 142(6), 1503–1527. https://doi.org/10.1093/brain/awz099
- Ngandu, T., Lehtisalo, J., Solomon, A., Levälahti, E., Ahtiluoto, S., Antikainen, R., et al. (2015). A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): A randomised controlled trial. The Lancet, 385(9984), 2255–2263. https://doi.org/10.1016/S0140-6736(15)60461-5
- Palmqvist, S., Whitson, H. E., Allen, L. A., Suárez-Calvet, M., Galasko, D., Karikari, T. K., et al. (2025). Alzheimer's Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer's disease within specialized care settings. Alzheimer's & Dementia, 21(7), e70535. https://doi.org/10.1002/alz.70535
- Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999). Mild cognitive impairment: Clinical characterization and outcome. Archives of Neurology, 56(3), 303–308. https://doi.org/10.1001/archneur.56.3.303
- Petersen, R. C., Lopez, O., Armstrong, M. J., Getchius, T. S. D., Ganguli, M., Gloss, D., et al. (2018). Practice guideline update summary: Mild cognitive impairment. Neurology, 90(3), 126–135. Historical guideline; subsequently retired. https://doi.org/10.1212/WNL.0000000000004826
- Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., et al. (2011). Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain, 134(9), 2456–2477. https://doi.org/10.1093/brain/awr179
- Sims, J. R., Zimmer, J. A., Evans, C. D., Lu, M., Ardayfio, P., Sparks, J., et al. (2023). Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA, 330(6), 512–527. https://doi.org/10.1001/jama.2023.13239
- Spector, A., Thorgrimsen, L., Woods, B., Royan, L., Davies, S., Butterworth, M., & Orrell, M. (2003). Efficacy of an evidence-based cognitive stimulation therapy programme for people with dementia: Randomised controlled trial. The British Journal of Psychiatry, 183(3), 248–254. https://doi.org/10.1192/bjp.183.3.248
- SPRINT MIND Investigators for the SPRINT Research Group. (2019). Effect of intensive vs standard blood pressure control on probable dementia: A randomized clinical trial. JAMA, 321(6), 553–561. https://doi.org/10.1001/jama.2018.21442
- Stern, Y. (2012). Cognitive reserve in ageing and Alzheimer's disease. The Lancet Neurology, 11(11), 1006–1012. https://doi.org/10.1016/S1474-4422(12)70191-6
- van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., et al. (2023). Lecanemab in early Alzheimer's disease. The New England Journal of Medicine, 388(1), 9–21. https://doi.org/10.1056/NEJMoa2212948
- World Health Organization. (2019). Risk reduction of cognitive decline and dementia: WHO guidelines. World Health Organization. https://www.who.int/publications/i/item/risk-reduction-of-cognitive-decline-and-dementia
- World Health Organization. (2026, July 15). New WHO guidelines: Up to 45% of dementia risk could be prevented or delayed. https://www.who.int/news/item/15-07-2026-new-who-guidelines--up-to-45--of-dementia-risk-could-be-prevented-or-delayed
- World Health Organization. (2026, July 3). Dementia [Fact sheet]. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/dementia
- World Health Organization. (2026). Risk reduction of cognitive decline and dementia: WHO guidelines (2nd ed.). World Health Organization. https://www.who.int/publications/i/item/9789240123557
- Zhang, X., Li, H., Li, Y., Hao, X., Yasen, A., Zheng, X., et al. (2026). Incidence of cognitive impairment post first stroke: A systematic review and meta-analysis. Frontiers in Neurology, 17, 1782749. https://doi.org/10.3389/fneur.2026.1782749